Coronado Biosciences Inc (CNDO) is eyeing significant commercial opportunity in its development of a revolutionary parasite treatment for autoimmune disease and could see breakthrough results that could benefit sufferers of Crohn’s disease, ulcerative colitis, and systemic autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, says Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.
“A majority of pharmaceuticals in development are generally incremental compared to their prior generation drug. Coronado is using a parasite to treat autoimmune disease. That’s very fascinating, and both scientifically and commercially, it’s a fascinating story based on the hygiene hypothesis,” Peaker said. “If you look at people in Third World countries, or pretty much the rest of the world or the entire world, over 100 years ago almost 100% of the population had intestinal parasites. The majority of them were not harmful to us, but they were there. What’s interesting is the moment we started to get rid of these parasites and started cleaning up our world, we started getting a lot of autoimmune disease.”
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
CNDO is now developing a treatment in which they take people with autoimmune disease and deliver a tiny parasite, invisible to the human eye, to the intestine, Peaker says. The first initial placebo control data is expected in the second half of the year, and if the results are positive, the treatment could be a scientific breakthrough and open up tremendous commercial opportunities, Peaker adds.
“If that does work, and you could start having this kind of treatment for Crohn’s disease, ulcerative colitis and ultimately systemic autoimmune diseases like multiple sclerosis or rheumatoid arthritis, you name it, the results would be revolutionary. That would be a huge breakthrough in science, because it would certainly help with one of the newer diseases that currently we treat with very expensive drugs and in a very crude fashion,” Peaker said.
Coronado Biosciences (CNDO) Uses Trichuris Suis Ova to Treat Autoimmune Diseases
May 20, 2013
Goldcorp (GG) Expands Gold Mining with Discipline; Gold Fields Ltd. (GFI) Sees Revalue Opportunity
December 19, 2012
Celgene Corporation (CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane
April 29, 2013
Investment Partners Asset Management Sees Opportunity in Closed End Fund Investing at a Discount to Net Asset Price
January 30, 2019
PNC Financial Services Sees Opportunity in Volatility in 2020
February 18, 2020
